GE

ImmunoGen initiates phase I trial in non-Hodgkin's lymphoma

Wednesday, April 18, 2012 12:14 PM

ImmunoGen, a biotechnology company that develops anticancer therapeutics using Targeted Antibody Payload (TAP) technology, has begun a phase I trial of its IMGN529 anticancer compound.

More... »

Lonza and Agennix to collaborate on talactoferrin

Monday, April 16, 2012 12:49 PM

Switzerland-based Lonza and Germany-based Agennix have signed an agreement for the production of Agennix’s talactoferrin.

More... »

Seattle Genetics, Millennium, Ventana collaborate on companion diagnostic test for Adcetris

Friday, April 13, 2012 12:37 PM

Seattle Genetics and Millennium, a subsidiary of Takeda Pharmaceutical, have formed a collaboration with Ventana Medical Systems, a member of the Roche Group, through which Ventana will seek to develop, manufacture and commercialize a molecular companion diagnostic test with the goal of identifying patients who might respond to treatment with Adcetris based on CD30 expression levels in their tissue specimens.

More... »

GE Healthcare launches Centricity EDI Services 5.4

Wednesday, April 11, 2012 10:15 AM

GE Healthcare IT has launched the newest version of Centricity EDI Services (5.4), a proven eligibility, claim and remittance clearinghouse for hospitals and physician practices.

More... »

Genstar Capital to acquire ERT

Tuesday, April 10, 2012 11:24 AM

Philadelphia-based eResearch Technology, a technology-driven provider of health outcomes research services to sponsors and CROs, has agreed to be acquired by affiliates of Genstar Capital, a middle market private equity firm, for $8 per share in cash in a transaction valued at approximately $400 million.

More... »

Amgen to acquire KAI Pharmaceuticals

Tuesday, April 10, 2012 11:21 AM

Amgen of Thousand Oaks, Calif., has agreed to acquire South San Francisco-based KAI Pharmaceuticals, a privately held pharmaceutical company.  KAI's lead product candidate, KAI-4169, is a novel agent being initially studied for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) who are on dialysis. Amgen will acquire worldwide rights, excluding Japan, to KAI-4169.

More... »

NY Genome Center receives $3 million grant, creates 500 jobs

Monday, April 9, 2012 12:20 PM

The Alfred P. Sloan Foundation has given a $3 million grant to independent non-profit New York Genome Center (NYGC) to help build the infrastructure needed to support a large-scale genome sequencing and bioinformatics facility for translational research.

More... »

Presage and Millennium enter cancer research agreement

Monday, April 9, 2012 09:59 AM

Presage Biosciences, a Seattle, Wash.-based company that identifies clinically viable oncology drug combinations, has entered into a cancer research agreement with Millenium, Takeda’s oncology arm based in Cambridge, Mass.

More... »

UCB, Amgen begin phase III postmenopausal osteoporosis program

Friday, April 6, 2012 03:47 PM

UCB, a global biopharmaceutical based in Brussels, Belgium, and biotech Amgen have initiated their sclerostin antibody (CDP7851/AMG785) phase III clinical trial program for the treatment of postmenopausal osteoporosis.

More... »

Takeda joins SGC, funds drug research

Friday, April 6, 2012 11:34 AM

Takeda Pharmaceutical has joined the Structural Genomics Consortium (SGC), based at the Universities of Toronto and Oxford, England, to fund collective drug research aimed at bringing new, more effective medicines to market faster.

More... »